| ORIGINAL ARTICLE |
|
| Year : 2019 | Volume
: 16
| Issue : 2 | Page : 108-111 |
|
|
Prevalence of hepatitis B and C in thalassemic patients and its relation with type of thalassemia, frequency of blood transfusion, and spleen status
Liqaa Mohammed Al-Sharifi, J Murtadha, A Shahad, Y Mohammed, J Sura, Z Waleed, M Raheeq, A Sura, H Ehab, M Shahad, Q Abbas
Department of Pathology, Babylon University/College of Medicine, Al-Hillah, Babylon Province, Iraq
Correspondence Address:
Liqaa Mohammed Al-Sharifi
Babylon University/College of Medicine, Al Hillah, Babil
Iraq
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/MJBL.MJBL_6_19
|
|
|
Background: Thalassemia is one of the most common inherited diseases; it is an inherited impairment of hemoglobin production, in which there is partial or complete failure of the synthesis of globin chain. Hepatitis B and hepatitis C had emerged as a major cause of end-stage liver disease. Both the viruses are transfusion-transmitted disease. Objective: The objective of the study is to assess the prevalence of hepatitis B and C viruses in thalassemic patients and its relation with type of thalassemia, blood transfusion, and spleen status. Material and Methods: A cross-sectional study was conducted on 100 multitransfused thalassemic patients for 2 months from November 1, 2016, to January 1, 2017. Test for HBsAg., HBcAb. IgG and IgM for screening of hepatitis B virus (HBV). HBcAb. by VIDAS method and confirmation by reverse transcription polymerase chain reaction for hepatitis C virus (HCV) was done. There is no family history of HBV and HCV infection nor vaccination history of the studied population. Results: Twelve (12%) patients had a positive HBcAb, while 3 (3%) had HBsAg positivity, higher percentage of HCV-infected patients (91%) received regular every 1-month blood transfusion, 50% of hepatitis C patients had splenomegaly, and 20.7% had splenectomy. Conclusion: Good and sensitive screening tests and stringent donor selection processes are required for the better control of this transfusion-transmitted infection among thalassemic patients.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
